Publications by authors named "K Amrane"

Claim this Profile
D
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.
Mariana Brandão, Elena Prisciandaro, Eleni Xenophontos, Alessio Mariolo, Amir H Sadeghi, Karim Amrane

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival impact of a KEAP1-NFE2L2 radiomics model in PDL1 ≥ 50% non-small cell lung cancer treated with pembrolizumab: the PEMBROMIC study.
Coline Le Meur, Karim Amrane, Renaud Descourt, Matthieu Chasseray, Olivier Pradier

Cancer Imaging· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.
K Amrane, B Cabarrou, G Justeau, S Schneider, X Quantin

ESMO Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.
Karim Amrane, Pierre Le Noac'h, Patrice Hemon, Ronan Abgral, Coline Le Meur

Melanoma Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018).
Romain Corre, Chantal Decroisette, Jean-Bernard Auliac, Lionel Falchero, Hubert Curcio, Karim Amrane

Clin Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis